The value of innovation : the economics of targeted drugs for cancer
作者： Cara C. Tigue , Karen A. Fitzner , Motasem Alkhatib , Eric Schmid , Charles L. Bennett
DOI: 10.1007/S11523-007-0043-8
关键词:
摘要: Oncology therapeutics have entered a new era, with the recent approval by US Food and Drug Administration of 16 novel targeted agents. In many instances, these agents led to breakthroughs in cancer care, such as imatinib for treatment chronic myeloid leukemia bevacizumab colorectal, lung, breast cancers. Toxicities are also novel-no longer primarily resulting hematologic, gastrointestinal, skin toxicities. As all innovative therapies, price tags substantial, ranging from mean per person annual cost $13,000 $100,000 cases. Despite high drugs, value has been important. this paper, we review concepts effectiveness they apply provide some initial insights on economics oncology drugs.
springer.com
sci-hub.se 参考文章(15)
Alex Berenson, Cancer drugs offer hope, but at huge expense. The New York times on the Web. ,(2005)
Alex Berenson, A cancer drug shows promise, at a price that many can't pay. The New York times on the Web. ,(2006)
R Bicknell, The realisation of targeted antitumour therapy. British Journal of Cancer. ,vol. 92, ,(2005) , 10.1038/SJ.BJC.6602602
E. Segota, R. M Bukowski, The promise of targeted therapy: Cancer drugs become more specific Cleveland Clinic Journal of Medicine. ,vol. 71, pp. 551- 560 ,(2004) , 10.3949/CCJM.71.7.551
Deborah Schrag, The price tag on progress--chemotherapy for colorectal cancer. The New England Journal of Medicine. ,vol. 351, pp. 317- 319 ,(2004) , 10.1056/NEJMP048143
Jennifer Bowman, Amy Rousseau, David Silk, Catherine Harrison, Access To Cancer Drugs In Medicare Part D: Formulary Placement And Beneficiary Cost Sharing In 2006 Health Affairs. ,vol. 25, pp. 1240- 1248 ,(2006) , 10.1377/HLTHAFF.25.5.1240
Barbara J. Culliton, Science For Life: A Conversation With Nobel Laureate David Baltimore Health Affairs. ,vol. 25, pp. W235- W240 ,(2006) , 10.1377/HLTHAFF.25.W235
Joseph A. DiMasi, Henry G. Grabowski, Economics of New Oncology Drug Development Journal of Clinical Oncology. ,vol. 25, pp. 209- 216 ,(2007) , 10.1200/JCO.2006.09.0803
M. Robyn Andersen, Nicole Urban, Scott Ramsey, Peter A. Briss, Examining the cost-effectiveness of cancer screening promotion. Cancer. ,vol. 101, pp. 1229- 1238 ,(2004) , 10.1002/CNCR.20511
John D. Graham, Phaedra S. Corso, Jill M. Morris, Maria Segui-Gomez, Milton C. Weinstein, EVALUATING THE COST-EFFECTIVENESS OF CLINICAL AND PUBLIC HEALTH MEASURES Annual Review of Public Health. ,vol. 19, pp. 125- 152 ,(1998) , 10.1146/ANNUREV.PUBLHEALTH.19.1.125